Perilla for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Perilla for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Perilla seed oil is the richest food source of plant omega-3 fat; its leaf carries separate anti-allergic compounds. It reliably raises plant omega-3 in blood cells, but blood-fat, inflammation, bone, joint, gut and thinking results stay modest or unrepeated. Conversion into fish forms is poor, so perilla complements rather than replaces marine oils. Seed allergy and rapid spoilage are real. (Full Review)

Protocol

Standard seed-oil protocol
6–7 mL daily
Roughly 6 g, about 3.5–4 g α-linolenic acid; unheated, with a meal
Leaf-extract protocol
50–200 mg daily
Rosmarinic-acid-standardised extract for allergic rhinitis; the knee-pain trial used 700 mg twice daily of whole leaf extract
Best time of day
With the largest fat-containing meal
Typically dinner; split dosing is preferred above 3 g daily
Time to effect
Membrane fatty-acid changes
8–12 weeks
Steady state; a repeat fatty-acid panel at 12 weeks confirms the shift
Lipid and inflammatory marker changes
8–12 weeks
Clearest where starting blood lipids and C-reactive protein are poor
Allergic-rhinitis symptom relief
21 days
Leaf extract commonly run 8–12 weeks spanning pollen season

Benefits

Contraindications
  • Documented perilla seed, shiso, or sesame-family seed allergy
  • Inherited bleeding disorder (haemophilia, von Willebrand disease)
  • Platelet count below 50,000/µL from any cause
  • Within 14 days of planned surgery or spinal or epidural anaesthesia
  • Child-Pugh Class C liver disease
  • Children under 3 years
    •
Key Interactions
  • Vitamin K antagonists (warfarin, acenocoumarol)
  • Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran)
  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor)
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac)
  • Antihypertensives (amlodipine, lisinopril, losartan)
  • Orlistat and bile acid sequestrants (cholestyramine, colesevelam)
  • Fish oil and algal EPA/DHA supplements
  • Supplements with additive antiplatelet effect (high-dose vitamin E, garlic extract, Ginkgo biloba, curcumin, nattokinase)
  • Antihistamines and intranasal corticosteroids (cetirizine, mometasone)
  • Perillyl alcohol and chemotherapy
    •

Risk & Side Effects

  • High: Immediate-type perilla seed allergy and anaphylaxis
    •
  • Medium: Poor conversion to eicosapentaenoic acid and docosahexaenoic acid; rapid oxidation and peroxide exposure; gastrointestinal adverse events at medicinal doses
  • Low: Occupational allergic contact dermatitis; increased bleeding tendency with antithrombotic therapy; cancer risk signals at high α-linolenic acid intake
  • Speculative: Perilla ketone pulmonary injury
    •

Monitoring

Marker Target Why
Red-cell α-linolenic acid No established target; track change from own baseline Confirms the oil is being absorbed and incorporated
Omega-3 Index (eicosapentaenoic plus docosahexaenoic acid) 8–12% Shows whether conversion is delivering usable long-chain omega-3
Triglycerides <80 mg/dL Primary lipid endpoint responsive to α-linolenic acid
Apolipoprotein B <80 mg/dL, or <60 mg/dL with established vascular disease Catches the low-density lipoprotein rise seen in pooled α-linolenic acid trials
High-sensitivity C-reactive protein <0.5 mg/L Tracks the inflammatory effect that α-linolenic acid trials consistently show
Platelet count and complete blood count 150,000–400,000/µL Baseline against which any bleeding tendency is judged
International normalised ratio Within individual anticoagulation target, typically 2.0–3.0 Detects potentiation of vitamin K antagonists
Serum tartrate-resistant acid phosphatase 5b Lower half of the adult reference range The bone-resorption marker that moved in the 12-month perilla trial
Prostate-specific antigen <1.0 ng/mL at age 40–50, <2.0 ng/mL thereafter Addresses the unresolved prostate signal at high α-linolenic acid intake
Alanine aminotransferase <25 U/L in men, <20 U/L in women Confirms concentrated preparations are not stressing the liver

Cadence: Fatty-acid panel, lipids, and high-sensitivity C-reactive protein at 12 weeks, then every 6–12 months; international normalised ratio at 2 weeks after starting and after every dose change; prostate-specific antigen and liver enzymes annually

Qualitative Assessment

  • Nasal and ocular allergy symptom burden, scored daily on a simple 0–10 scale through pollen season
  • Bruising frequency and any nosebleeds, gum bleeding, or unusually prolonged bleeding from minor cuts
  • Bowel regularity and stool form, since both improved in the gut-microbiome trial
  • Joint comfort during stairs and prolonged sitting, the specific domains that moved in the knee-pain trial
  • Energy, mood, and mental clarity, which improved alongside antioxidant potential in the Japanese cohorts
  • Taste and smell of the oil itself — a paint-like or fishy note signals oxidation and is a reason to discard the bottle
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.